Caution may still be warranted with selective COX-2 inhibitors in noncardiac surgery patients with significant cardiovascular disease, but these risks may not be significant when exposure is limited to short-term perioperative use [ 183 , 212 , 223 , 224 , 225 ].
1
—
—